Dataset Information

Incidence of Asymptomatic Brain Metastases in Metastatic Colorectal Cancer.

ABSTRACT:

Background

Current literature suggests that brain metastasis is an infrequent occurrence in metastatic colorectal cancer. Outside of rare autopsy studies, these retrospective reports describe the incidence of symptomatic brain metastasis and therefore lack a description of the incidence in asymptomatic patients. With improved survival and a lack of routine brain imaging, the true incidence of brain metastasis among patients with metastatic colorectal cancer is likely under-recognized. At our research institution, protocol criteria require brain imaging regardless of neurologic symptoms. Therefore, we aim to describe the incidence of asymptomatic brain metastases in patients with metastatic colorectal cancer.

Patients and methods

This study included patients with metastatic colorectal cancer enrolled onto a clinical trial screening protocol at the National Cancer Institute that underwent brain imaging (n = 171) between 2010 and 2019.

Results

The median age of patients at initial colorectal cancer diagnosis was 48.1 years. Most had stage IV disease with synchronous metastases. Twenty-five (14.6%) patients were identified with brain metastases, of which 19 (76%) were asymptomatic. Those with asymptomatic lesions were more likely to have presented with synchronous metastases, have a shorter time from primary diagnosis to development of metastatic disease, and have smaller brain metastases.

Conclusion

We identified a high number of asymptomatic brain metastasis and subsequently a higher cumulative incidence of brain metastases in patients with metastatic colorectal cancer than historical reports would suggest. This may represent a heretofore unknown aspect of the natural course of disease now being exposed owing to an increasing life expectancy of these patients and could play a pivotal role in therapeutic decisions.

SUBMITTER: Shindorf ML

PROVIDER: S-EPMC8293021 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:AimTo investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.MethodsWe compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts: (1) the AGITG MAX trial (Phase III randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine, bevacizumab and mitomycinC); (2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry (any first-line regimen ± bevacizumab); and (3) two cancer centres in New South Wales, Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre (NSWCC) from January 2005 to Decenber 2012, (any first-line regimen ± bevacizumab). For the AGITG MAX trial capecitabine was compared to the other two arms (capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycinC). In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases. Secondary endpoints included progression-free survival, chemotherapy duration, and overall survival. Time-to-event outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.ResultsEighty-four MAX, 179 TRACC and 69 NSWCC patients had peritoneal disease. There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts. Of the patients without peritoneal disease in the MAX trial, 4/300 (1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123 (0.8%) in the capecitabine alone arm. In the TRACC registry 3/126 (2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53 (1.9%) in the chemotherapy alone arm. In a further analysis of patients without peritoneal metastases in the TRACC registry, the rate of gastrointestinal perforations was 9/369 (2.4%) in the chemotherapy/bevacizumab group and 5/177 (2.8%) in the chemotherapy alone group. The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts: MAX 6.9 m vs 4.9 m, HR = 0.64 (95%CI: 0.42-1.02); P = 0.063; TRACC 9.1 m vs 5.5 m, HR = 0.61 (95%CI: 0.37-0.86); P = 0.009; NSWCC 8.7 m vs 6.8 m, HR = 0.75 (95%CI: 0.43-1.32); P = 0.32. Chemotherapy duration was similar across the groups.ConclusionPatients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone.